This Changes Everything About Nattokinase & Clogged Arteries (New Study)

Summary

The video discusses nattokinase, an enzyme derived from natto (fermented soybeans), and a study the presenter says found that nattokinase’s ability to break down clots may vary by blood type and age.

What nattokinase is said to do

The presenter describes enzymes as proteins that speed up chemical reactions. Nattokinase is presented as acting on fibrin, the protein mesh that helps hold a blood clot together. By breaking down this mesh, nattokinase may help clots dissolve.

Clots can obstruct blood flow and deprive downstream tissue of oxygen, as can happen during heart attacks and strokes.

Study described in the video

The presenter says a study published in Scientific Reports in February 2026 investigated whether nattokinase breaks down clots at the same rate in different people.

The reported methodology included:

• Testing nearly 1,800 blood samples from people aged 10–70, spanning the eight ABO/Rh blood-type combinations.
• Forming clots under controlled laboratory conditions, adding nattokinase, and measuring how long the clots took to dissolve.
• Using electron microscopy and molecular analysis to examine clot structure and investigate differences in dissolution.
• Checking the findings in a separate group of 562 samples from nine cities.

These were laboratory (“in vitro”) tests, not tests of clinical outcomes in people taking nattokinase.

Findings as presented

• The reported ranking from fastest to slowest clot dissolution was O, B, A, then AB.
• The presenter says O-positive samples dissolved fastest and AB-negative samples slowest, with a reported difference of nearly 20 minutes between the fastest and slowest responses.
• The proposed explanation involves von Willebrand factor, which helps stabilize clots. The presenter says people with type O generally have lower levels, potentially making their fibrin mesh less dense and easier for nattokinase to break down.
• The video also suggests that Rh-positive status may be associated with an additional protein that could affect nattokinase’s action. The presenter notes that this aspect is still being studied.
• Age is described as another important factor. The presenter says the body’s natural clot-dissolving capacity declines with age and identifies AB-negative participants aged 66–70 as the least favorable combination in the study.

Interpretation and practical points

The presenter’s main takeaway is that biological differences may affect how a supplement works, but laboratory findings do not automatically translate into dosing advice.

As described in the video, the study does not establish that people with particular blood types should take higher doses. It also does not show that nattokinase prevents heart attacks or strokes.

The presenter advises viewers to know their blood type and discuss nattokinase with a knowledgeable clinician rather than assume it is effective—or ineffective—for a particular person. The video also cautions that supplements are not necessarily harmless and says bleeding risk may be greater at higher doses, particularly when nattokinase is combined with aspirin or other blood-thinning medicines.

The presenter offers 200 fibrinolytic units as a starting point for a “typical patient” and says any increase should be gradual, every two to four weeks, under medical supervision. This is the presenter’s advice, not a dosing recommendation demonstrated by the study.

The video emphasizes checking with a clinician before changing treatment, especially for people taking blood thinners or with other relevant health conditions.

Speakers and sources featured

• Dr. Ford Brewer — the sole speaking presenter in the subtitles.
• Researchers behind the study described as published in Scientific Reports — discussed by the presenter; no individual researchers are named in the subtitles.
• ** Scientific Reports ** — named as the publication source for the study.